GlassScriptPhysician profile
Nilesh Verma
NPI 1346685526
$26,975.88
in general payments reported to CMS, 2019-2025
30 companies · $26K in 2025
The $26K reported for 2025 was more than what 91% of Medical Oncology providers received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $111 · 2021: $42.07 · 2022: $449 · 2023: $306 · 2024: $124 · 2025: $26K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $16K · Consulting Fee: $7,910 · Travel and Lodging: $1,849 · Food and Beverage: $978 · Education: $37.21.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $15,600.00 |
| Consulting Fee | $7,910.00 |
| Travel and Lodging | $1,848.64 |
| Food and Beverage | $977.93 |
| Education | $37.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Beone Medicines USA, INC. | $17,415.01 | 2025 | Tevimbra |
| Beigene USA, INC. | $4,711.62 | 2025 | Tevimbra |
| Astrazeneca Uk Limited | $3,685.00 | 2025 | |
| Ipsen Biopharmaceuticals, INC | $145.25 | 2023 | Somatuline Depot, Onivyde |
| Amgen INC. | $142.09 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $110.13 | 2022-2023 | |
| Immunitybio, INC. | $98.59 | 2025 | |
| Astellas Pharma US INC | $95.56 | 2023-2024 | Padcev |
| Janssen Biotech, INC. | $84.98 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $50.83 | 2022-2023 | Abecma |
| Astrazeneca Pharmaceuticals LP | $37.25 | 2022 | |
| Array Biopharma INC | $36.24 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $35.82 | 2021-2023 | |
| Emmaus Medical, INC. | $34.47 | 2023-2024 | Endari |
| Pfizer INC. | $31.82 | 2022 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Puma Biotechnology, INC. | $27.59 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $25.94 | 2024 | Alunbrig |
| Gilead Sciences, INC. | $24.52 | 2021 | |
| Intuitive Surgical, INC. | $21.89 | 2023 | |
| Incyte Corporation | $19.13 | 2024 | Monjuvi |
| Servier Pharmaceuticals LLC | $19.04 | 2025 | |
| Regeneron Healthcare Solutions, INC. | $17.73 | 2022 | |
| Myriad Genetic Laboratories, INC. | $17.09 | 2022 | |
| Glaxosmithkline, LLC. | $16.02 | 2022 | |
| Lilly USA, LLC | $15.97 | 2022 | |
| Merck Sharp & Dohme LLC | $15.48 | 2024 | Keytruda |
| Tempus Ai, INC | $14.95 | 2025 | Xt Cdx |
| Sobi, INC | $13.07 | 2022 | |
| Eisai INC. | $12.80 | 2022 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nilesh Verma listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.